Bayer AG (ETR: BAYN) announced that its drug Hyrnuo (sevabertinib) received approval from China’s National Medical Products Administration (NMPA) for a new indication — the treatment of adult patients with unresectable locally advanced or metastatic non‑small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations, expanding the oral tyrosine kinase inhibitor from the previously approved second‑line setting into first‑line therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | New indication expansion |
| Product | Hyrnuo (sevabertinib) – oral small‑molecule TKI |
| New Indication | Adult patients with unresectable locally advanced or metastatic NSCLC harboring activating HER2 (ERBB2) mutations |
| Prior Approval | Monotherapy for the same population after at least one prior systemic therapy |
| Supporting Evidence | Ongoing Phase I/II SOHO‑01 trial (NCT05099172) |
| Approval Date | Announced 4 Nov 2026 |
Drug Profile & Mechanism of Action
- Molecule: Sevabertinib, an oral small‑molecule tyrosine kinase inhibitor (TKI) marketed as Hyrnuo.
- Target: Activating HER2 (ERBB2) mutations — oncogenic drivers in a defined subset of NSCLC patients.
- Clinical Setting Expansion: The new approval moves sevabertinib into the treatment‑naive (first‑line) population, following its prior China approval as monotherapy in previously treated locally advanced or metastatic HER2‑mutant NSCLC.
- Safety Profile: The safety profile in the SOHO‑01 trial was consistent with findings from previous studies.
Clinical Evidence – SOHO‑01 Phase I/II Trial
| Endpoint | Result (Treatment‑Naive Cohort, n = 73) |
|---|---|
| Objective Response Rate (ORR) | 75.3 % |
| Complete Response (CR) | 5.5 % |
| Partial Response (PR) | 69.9 % |
| Durability – Responders with DoR ≥ 6 Months | 72.7 % |
| Safety | Consistent with previous studies |
The approval is based on results from the ongoing Phase I/II SOHO‑01 clinical trial (NCT05099172), which evaluates the efficacy and safety of sevabertinib in patients with locally advanced or metastatic HER2‑mutant NSCLC. In the cohort of 73 treatment‑naive patients, the ORR reached 75.3 %, with 5.5 % achieving a complete response and 69.9 % a partial response; notably, 72.7 % of responding patients sustained their response for at least six months.
Market Impact & Outlook
- First‑Line Positioning: Moving into the treatment‑naive setting substantially expands the addressable HER2‑mutant NSCLC population in China, positioning Hyrnuo ahead of the later‑line usage pattern of its prior approval.
- China HER2‑Mutant NSCLC Landscape: HER2 (ERBB2) mutations occur in a defined minority of NSCLC patients, historically underserved by targeted options — an oral TKI with a 75.3 % first‑line ORR and durable responses addresses a significant unmet need.
- Oncology Franchise Growth: The indication expansion reinforces Bayer’s oncology portfolio momentum in China, one of the company’s key growth markets for its Pharmaceuticals Division.
- Competitive Edge: As an oral first‑line option with demonstrated response durability, sevabertinib competes favorably against intravenous antibody‑drug conjugate approaches in the HER2‑mutant NSCLC space.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of Hyrnuo (sevabertinib), the ongoing SOHO‑01 trial, and market potential in China. Actual results may differ materially due to risks including further clinical data, regulatory requirements, market adoption, reimbursement dynamics, and competitive developments.-Fineline Info & Tech
